Market Place
Sourcing Support
Medincell to Join the Euronext SBF 120 Index
12 Dec 2024 //
BUSINESSWIRE
Medincell Increases 2024 UZEDY® Revenue Outlook by 25%
06 Nov 2024 //
BUSINESSWIRE
Medincell Presents New Data On Olanzapine For Schizophrenia
23 Sep 2024 //
BUSINESSWIRE
Medincell`s Partner Teva Provides UZEDY Treatment Insights
23 Sep 2024 //
BUSINESSWIRE
Medincell’s Partner Teva Updates on Phase 3 of Olanzapine Long-Acting Injectable
05 Sep 2024 //
BUSINESSWIRE
Medincell Announces Progress in Products Portfolio and R&D Pipeline
03 Sep 2024 //
BUSINESSWIRE
Medincell`s Partner Teva Updates On Olanzapine LAI And UZEDY®
31 Jul 2024 //
BUSINESSWIRE
Medincell Publishes Its Consolidated Annual Financial Results
10 Jun 2024 //
BUSINESSWIRE
Adaptimmune’s debt financing deal; Tenaya to cut workers
15 May 2024 //
ENDPTS
Teva and MedinCell`s long-acting schizophrenia med wins in phase 3
09 May 2024 //
FIERECE PHARMA
Teva and Medincell: Positive Phase 3 Results for TEV-‘749 in Schizophrenia
08 May 2024 //
BUSINESSWIRE
AbbVie inks deal for Medincell`s long-acting injectable platform worth up to $1.9B
17 Apr 2024 //
PRESS RELEASE
Medincell, AbbVie Partner On Next-Gen Long-Acting Injectables
16 Apr 2024 //
BUSINESSWIRE
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
08 Apr 2024 //
BUSINESSWIRE
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024
31 Jan 2024 //
BUSINESSWIRE
Teva Announces Recruitment Completion of Phase 3 Clinical Study of Olanzapine
09 Jan 2024 //
BUSINESSWIRE
MedinCell Applauds Teva and Royalty Pharma Collaboration
13 Nov 2023 //
BUSINESSWIRE
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell
06 Sep 2023 //
BUSINESSWIRE
MedinCell announces successful completion of patient in the Ph3 study of F1
30 Aug 2023 //
BUSINESSWIRE
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
02 Aug 2023 //
BUSINESSWIRE
MedinCell: mdc-TJK`s (Teva`s codename: TEV-44749) pH 1 study pharmacokinetics
04 May 2023 //
BUSINESSWIRE
FDA approves Teva, MedinCell`s long-acting schizophrenia therapy
02 May 2023 //
FIERCE PHARMA
Teva and MedinCell Announce FDA Approval of UZEDY Injectable Suspension
28 Apr 2023 //
BUSINESSWIRE
MedinCell receives “Prime” ISS ESG rating as a recognition
23 Feb 2023 //
BUSINESSWIRE
Teva takes 2nd long-acting schizophrenia drug into phase 3
01 Feb 2023 //
FIERCE PHARMA
MedinCell announces positive results for SAIVE study in prevention of Covid-19
05 Jan 2023 //
BUSINESSWIRE
Additional US$ 4M Received for Next DeVP Steps of MedinCell`s 6-Month Active Inj
30 Nov 2022 //
BUSINESSWIRE
France : EIB and MedinCell Sign a New €40 Million Loan Agreement
23 Nov 2022 //
BUSINESSWIRE
MedinCell’s Partner Teva Today Announced Refiling for Approval of mdc-IRM
03 Nov 2022 //
BUSINESSWIRE
MedinCell Signs a Licence Agreement With the Medicines Patent Pool
13 Sep 2022 //
BUSINESSWIRE
MedinCell Secures Additional 20 Million Euros Financing With the EIB
05 Sep 2022 //
BUSINESSWIRE
Phase 3 Study to Be Initiated for Injectable Antipsychotic
29 Aug 2022 //
BUSINESSWIRE
MedinCell Publishes Its 2021-2022 ESG Annual Report
17 Aug 2022 //
BUSINESSWIRE
Teva confirms expectation for approval and commercialization in the US
27 Jul 2022 //
BUSINESSWIRE
MedinCell: US Pharma Development Expert R. Malamut Becomes CMO
09 May 2022 //
BUSINESSWIRE
Teva Provides Additional Information Regarding the NDA for mdc-IRM
03 May 2022 //
BUSINESSWIRE
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
20 Apr 2022 //
BUSINESSWIRE
MedinCell provides additional information regarding the NDA for MDC-IRM
19 Apr 2022 //
BUSINESSWIRE
MedinCell Provides an Update on Its Product Portfolio
01 Sep 2021 //
BUSINESSWIRE
FDA accepts NDA for Teva and MedinCell’s schizophrenia candidate
01 Sep 2021 //
THE PHARMA LETTER
Teva and MedinCell Announce FDA Acceptance of NDA for TV-46000/mdc-IRM
31 Aug 2021 //
BUSINESSWIRE
MedinCell’s Long-Acting Injectable to Fight Malaria
14 Jun 2021 //
BUSINESSWIRE
Teva and MedinCell announce positive results from phase 3 RISE study of TV-46000
08 Jan 2021 //
PHARMABIZ
Teva and MedinCell Announce Positive Results for Registration Trial of Investig
07 Jan 2021 //
BUSINESSWIRE
MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program
29 Sep 2020 //
BUSINESSWIRE
MedinCell launches Regulatory Development of mdc-WWM Program
22 Apr 2020 //
BUSINESSWIRE
MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience
06 Apr 2020 //
BUSINESSINSIDER
